公开(公告)号：WO2019173293A1

公开(公告)日：2019-09-12

申请号：PCT/US2019/020690

申请日：2019-03-05

申请人： SHIRE HUMAN GENETIC THERAPIES, INC.

发明人： DWYER, Brian ,  ZHANG, Bohong ,  HU, Jun ,  MEIYAPPAN, Muthuraman ,  MILLER, Thomas ,  MCLEAN, Paul ,  PAN, Clark

IPC分类号： C07K1/22

摘要： The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g ., a-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β- galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

公开(公告)号：WO2018144620A1

公开(公告)日：2018-08-09

申请号：PCT/US2018/016272

申请日：2018-01-31

申请人： SHIRE HUMAN GENETIC THERAPIES, INC.

发明人： MILLER, Thomas ,  PAPAIOANNOU, Nikolaos

IPC分类号： C07C235/38 ,  A61K31/167 ,  A61P17/00 ,  C07C235/40 ,  C07C237/20 ,  C07C255/60 ,  C07D205/04 ,  C07D207/12 ,  C07D207/24 ,  C07D209/46 ,  C07D211/22 ,  C07D211/26 ,  C07D211/46 ,  C07D211/58 ,  C07D213/30

摘要： Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))